Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBEST02 is an enzyme supplementation product candidate developed by AMYRA Biotech using its proprietary Brush Border Enzyme Supplementation Technology (BBEST). The product is designed to supplement or replace essential brush border enzymes that line the small intestine, which are often deficient or dysfunctional in individuals with various gastrointestinal conditions. By restoring these enzymatic activities, BBEST02 aims to improve the digestion of nutrients, mitigate food sensitivities, and manage symptoms associated with intestinal digestion disorders. It is currently positioned within AMYRA's consumer healthcare pipeline as a potential solution for improving nutritional uptake and gastrointestinal health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BBEST02.